Novel Treatment of Advanced Hepatocellular Carcinoma (NTAHCC)

  • STATUS
    Recruiting
  • days left to enroll
    70
  • participants needed
    300
  • sponsor
    The First Affiliated Hospital of Zhengzhou University
Updated on 7 February 2022
liver cancer
cancer
antiviral therapy
g-csf
primary liver cancer
antiviral drugs

Summary

The purpose of this study is to evaluate the efficacy and safety of arginine hydrochloride combined with Levamisole in the treatment of patients with hepatocellular carcinoma.

Description

Hepatocellular carcinoma (HCC) is the sixth most common cancer and the second leading cause of cancer-related deaths in the world. Because HCC is insidious and early diagnosis is difficult, most patients have locally advanced or distant metastasis at the time of diagnosis. So they are not suitable candidates for curative treatments by resection or transplantation. Currently, There are only not more than five drugs to be selected for advanced HCC, although it prolongs the survival for less than 3 months. Recently, metabolomics studies of HCC have shown that typical Warburg effect was observed in hepatoma carcinoma cells. Arginine hydrochloride is a new anticancer drug in the treatment of HCC, which is mainly aimed at the pathway of energy metabolism. levamisole may play an anti-tumor role by inhibiting the reverse TCA cycle. The investigators have been proceeding this trial to evaluate the efficacy and safety of arginine hydrochloride combined with levamisole in the treatment of patients with advanced hepatocellular carcinoma.

Details
Condition HCC
Treatment Arginine hydrochloride, Anlotinib Hydrochloride Capsules, levamisole, levamisole
Clinical Study IdentifierNCT03950518
SponsorThe First Affiliated Hospital of Zhengzhou University
Last Modified on7 February 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

\. Ages 18-65 years 2. The diagnosis of ICC: in accordance with "diagnostic and treating standards on primary liver cancer" or histological/cytological diagnosis of primary liver cancer 3. Un-resectable HCC : patients with developing primary liver cancer of Barcelona stage(BCLC) B; multiple nodules (less than 5, the total diameter of less than 20 cm), no invasion, no symptoms;refusing open surgical treatment and volunteering for the treatment 4. The First-line system therapy failure (or residual lesion) from the group of this study a signed informed consent (time) for 2 weeks or more basic returned to normal and adverse events (NCI CTCAE level or less); 5. Child-Pugh liver function class A/B(score: 7) 6. Performance status 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) scale in one week before admission 7. Estimated survival time > 3 months 8. HBV DNA#2000 IU/ml#10^4 copies/ml); or HBV DNA2000 IU/ml and are accepting effective antiviral therapy 9. The major organ function is normal. that is meeting the following standards
Blood routine examination: (No blood transfusion, no G-CSF and no medication
were corrected within 14 days before screening)
HB80g/L b.ANC1.5109/L c.PLT50109/L#
Biochemical examination: (ALB was not transfused within 14 days before
screening) a.ALB 29 g/L b.ALT AST<5ULN c.TBIL 3ULN d.creatinine
5ULN( albumin and bilirubin, two indicators of Child-Pugh liver function
class, can only have one for 2 points)
\. For women of childbearing age, the results of serum/urine pregnancy tests
must be negative within 7 days before initiation of treatment. All men and
women who participate in the study have to take reliable contraceptive
measures within the trial and eight weeks after the trial is completed
\. volunteers must signed informed consent

Exclusion Criteria

\. With a history of alimentary tract hemorrhage or a definite tendency of gastrointestinal bleeding, such as varices of fundus of stomach and esophagus with bleeding risk; local active ulcer lesions; fecal occult blood ++ 2\. Patients with hepatobiliary cell carcinoma, mixed cell carcinoma or lamellar cell carcinoma; in the past (within 5 years) or at the same time suffering from other untreated malignant tumors; excluding cured basal cell carcinoma and carcinoma in situs of cervix 3. Patients who are undergoing liver transplantation or have a history of organ transplantation(excluding the patient who has undergone liver transplantation before) 4. Patients with an allergic history of Levamisole Hydrochloride and Anlotinib Hydrochloride Capsules 5. The blood pressure can not be reduced to the normal range by the antihypertensive drug treatment in patients with hypertension(systolic pressure#140 mmHg, diastolic pressure#90 mmHg) 6. Patients with myocardial ischemia or myocardial infarction over grade II or a poorly controlled arrhythmia (including QTc interval: men 450 ms; women 470 ms) 7. Cardiac functional insufficiency of grade III to IV according to NYHA standard; echocardiography: LVEF#50% 8. Many factors that influence oral medication, such as unable to swallow; chronic diarrhea; intestinal obstruction; the situations which significantly affect the use and absorption of drugs 9. Abdominal fistula, gastrointestinal perforation, or abdominal abscess occurred within 28 days before participating the study 10. Dysfunction of blood coagulation(INR#2.0 or PT 16s APTT > 43s TT > 21sFbg < 2g/L), having a tendency to bleed or undergoing thrombolysis or anticoagulant therapy; ascites with clinical symptoms, that is requiring therapeutic abdominal paracentesis or drainage or Child-Pugh score 2 11. Objective evidence of pulmonary fibrosis history, interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug associated pneumonia, and severe lung function impairment in the past and at present 12. Urine routine showed that urine protein ++ or the urine protein in 24 hours#1.0 g 13. Patients who have been treated with potent CYP3A4 inhibitors (ketoconazole, itraconazole, voriconazole, ritonavir, clarithromycin, telithromycin, troleandomycin, erythromycin, cimetidine and so on) within 28 days before participating the study, or potent CYP3A4 inducers (dexamethasone, phenytoin, rifampin, rifabutin, carbamazepine, phenobarbitone and so on) within 12 days before participating the study. 14. Pregnant or lactating women; fertile patients who are unwilling or unable to adopt effective contraceptives 15. Patients with mental sickness or the history of psychotropic drug abuse 16. Patients with severe infection (unable to control the infection effectively) 17. The treatment history affecting this program or its efficacy, such as stem cell transplantation, immune regulation (including PD-1 and other test regimens) recently (within half a year) 18. The researchers believe that any other factors unsuitable for entering into the study
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note